OakChart

MBX Biosciences Inc

MBXHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 1:40 PM ET

56.97+0.63 (1.13%)
2026-11-11 19:40 CET
Market cap
2,712.86 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-145.09 USD m
Free cash flow, TTM
-99.33 USD m
EPS diluted, TTM
-3.06
P/E
-
Compare

Price

MBX against its 20, 50 and 200-day averages
2050200miss
40.0060.001.4M2.9MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MBXclose 56.9720-day 52.8050-day 56.00200-day 46.1356.9752w high52w low

21.6% under the 52-week high of 72.64 on 5 Aug 2026. 52-week low 23.07 on 14 Nov 2025. Last 15 sessions, 23.3% high to low

Profile

MBX
52-week range, 68% of the way up
23.0772.64

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

IndexRUT
Employees63
IPOSep 13, 2024
Beta0.20
ATR, 14d3.79
Rel volume0.72
Short float14.05%
Insider own36.67%
Inst own82.40%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap2.83B
Enterprise Value2.35B
Income-145.09M
Sales0.00M
Book/sh9.53
Cash/sh9.70
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees63
IPOSep 13, 2024

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B5.98
P/C5.87
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio19.58
Current Ratio19.58
Debt/Eq0.01
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.06
EPS next Y-4.27
EPS next Q-0.99
EPS this Y-46.63%
EPS next Y-22.23%
EPS next 5Y-24.96%
EPS past 3/5Y-44.91% -
Sales past 3/5Y- -
EPS Y/Y TTM-27.83%
Sales Y/Y TTM-
EPS Q/Q-103.37%
Sales Q/Q-
EarningsNov 09 AMC
EPS/Sales Surpr.-56.02% -

Ownership

Insider Own36.67%
Insider Trans-0.40%
Inst Own82.40%
Inst Trans2.37%
ROA-32.22%
ROE-33.72%
ROIC-30.52%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA207.88%
SMA501.72%
SMA20023.48%
Trades-

Technical

Shs Outstand49.64M
Shs Float30.50M
Short Float14.05%
Short Ratio8.30
Short Interest4.29M
52W High72.64 -21.58%
52W Low23.07 146.92%
Volatility9.41% 7.12%
ATR (14)3.79
RSI (14)56.09
Beta0.20
Rel Volume0.72
Avg Volume516.18K
Volume246,441

Performance

Perf Week8.55%
Perf Month16.26%
Perf Quarter-15.08%
Perf Half Y51.91%
Perf YTD80.61%
Perf Year128.68%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.09
Target Price95.60
Prev Close56.33
Price56.97
Change %1.13%

Analyst ratings

latest 10 of 13
DateActionAnalystRating changeTargetImplied
Aug 21, 2026ResumedJJP MorganOverweight$88+54.5%
Jan 28, 2026InitiatedBBarclaysOverweight$66+15.9%
Dec 04, 2025InitiatedGGoldmanSell$18-68.4%
Nov 04, 2025InitiatedTTD CowenBuy
Oct 15, 2025InitiatedTTruistBuy$50-12.2%
Aug 15, 2025ResumedJJefferiesBuy$36-36.8%
Aug 05, 2025InitiatedMMizuhoOutperform$38-33.3%
Jul 16, 2025InitiatedOOppenheimerOutperform$38-33.3%
Apr 10, 2025InitiatedCCitizens JMPMkt Outperform$38-33.3%
Oct 08, 2024InitiatedSStifelBuy$40-29.8%

Peers

Mkt cap
TickerCompanyMkt cap
ASNDAscendis Pharma A/S16.90B
KLRAKailera Therapeutics Inc1.86B
VKTXViking Therapeutics Inc3.69B
GPCRStructure Therapeutics Inc ADR1.52B
PTGXProtagonist Therapeutics Inc8.77B
ENTXEntera Bio Ltd558.99M
ALTAltimmune Inc376.39M
RYTMRhythm Pharmaceuticals Inc7.93B
RZLTRezolute Inc396.10M
SPRBSpruce Biosciences Inc134.15M

Insider trading

latest 14 of 27
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Hoerter Steven L.DirectorNov 10 '26Proposed Sale54.824,893268,248Nov 10 07:25 PM
Azoulay SalomonChief Medical OfficerNov 04 '26Sale53.9637320,12714,026Nov 05 04:10 PM
Azoulay SalomonOfficerNov 04 '26Proposed Sale53.9637320,127Nov 04 03:12 PM
Hawryluk P. KentFormer OfficerAug 17 '26Proposed Sale68.293,745255,737Aug 17 03:41 PM
Azoulay SalomonChief Medical OfficerAug 04 '26Sale65.7737024,33514,399Aug 05 04:57 PM
Hawryluk P. KentOfficerAug 04 '26Proposed Sale65.7793661,563Aug 04 04:44 PM
Azoulay SalomonOfficerAug 04 '26Proposed Sale65.7737024,336Aug 04 04:42 PM
Bartram RichardFormer OfficerJun 10 '26Proposed Sale30.559,167280,010Jun 10 12:41 PM
Bartram RichardFormer OfficerJun 09 '26Proposed Sale29.6610,833321,273Jun 09 04:38 PM
Bartram RichardFormer OfficerMay 13 '26Proposed Sale36.9515,000554,296May 13 04:17 PM
Azoulay SalomonChief Medical OfficerMay 08 '26Option Exercise11.6570,003815,34869,769May 11 04:01 PM
Azoulay SalomonChief Medical OfficerMay 08 '26Sale38.3670,0032,685,51514,769May 11 04:01 PM
Bartram RichardFormer OfficerMay 11 '26Proposed Sale44.0822,500991,901May 11 03:54 PM
Azoulay SalomonOfficerMay 08 '26Proposed Sale38.3770,0032,685,679May 08 04:10 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 516.35M
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
DFASU.S. Small Cap Portfolio-ETF Class Shares-

News

latest 14 of 174
  • MBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire) +5.28%
  • MBX Biosciences to Participate in Upcoming November Investor Conferences (GlobeNewswire) -5.81%
  • MBX Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer (GlobeNewswire)
  • MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism (GlobeNewswire)
  • UMH Properties and 4 More Stocks See Action From Activist Investors (Barrons.com)
  • MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire)
  • MBX Biosciences Announces Executive Leadership Transition to Support the Company's Next Phase of Growth (GlobeNewswire) -5.75%
  • MBX Biosciences Shares Fall Despite Positive One-Year Trial Results for Canvuparatide (MBX) (InvestorsHub)
  • MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism (GlobeNewswire)
  • J&J looks to widen Imaavys use; $300M backs rare disease drug launch (BioPharma Dive) +20.20%
  • MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026 (GlobeNewswire)
  • MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City (GlobeNewswire)
  • MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-1.290-0.827-1.2900.000.0010
2026Q22026-08-06-0.780-0.633-0.7780.000.0011
2026Q12026-05-07-0.510-0.585-0.5050.000.0011
2025Q42026-03-12-0.490-0.605-0.4920.000.0011
2025Q32025-11-06-0.630-0.692-0.6320.000.009
2025Q22025-08-07-0.580-0.735-0.5800.000.007
2025Q12025-05-12-0.710-0.770-0.7150.000.004
2024Q42025-03-17-0.470-0.573-0.4660.000.003
2024Q32024-11-07-2.780-2.717-0.5440.000.003
2024Q22024-08-28-11.470--0.4750.00--
2026Q4---0.986--0.0010
2027Q1---0.980--0.003
2027Q2---1.017--0.003
2027Q3---1.070--0.003
2027Q4---1.107--0.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-5.820-11.519-1.8530.000.00
2025FY-2.380-2.466-2.3810.000.00
2026FY--3.490--0.00
2027FY--4.266--0.00
2028FY--4.644--35.32
2029FY--2.927--156.65
2030FY--1.033--357.21

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-107000.000.000.00
2026Q4S2026-11-097000.000.000.00
2026Q4S2026-09-147000.000.000.00
2026Q4S2026-08-068000.000.000.00
2026Q4S2026-07-278000.000.000.00
2026Q4S2026-07-217000.000.000.00
2026Q4S2026-06-208000.000.000.00
2026Q4S2026-05-119000.000.000.00
2026Q4S2026-05-078000.000.000.00
2026Q4S2026-03-128000.000.000.00
2026Q4S2025-12-184000.000.000.00
2026Q4S2025-11-113000.000.000.00
2026Q4S2025-11-103000.000.000.00
2026Q4S2025-11-093000.000.000.00

Estimate history

EPS, annual-0.783-0.976-1.853-2.382-3.0598
Period2022202320242025TTM
EPS, quarterly-0.544-0.466-0.715-0.58-0.632-0.492-0.505-0.778-1.286
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00000
Period2022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual33.37633.37633.42244.92849.641
Period2022202320242025MRQ
Shares, quarterly33.37633.42233.42433.59244.71544.92847.5747.9549.641
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Total Revenue0.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.340.250.240.160.06
Gross Profit-0.34-0.25-0.24-0.16-0.06
Selling, General and Administrative Excl. Other159.9997.8167.9535.1525.11
Research and Development101.2779.1657.4128.5321.40
Other Operating Expense0.000.000.000.000.00
Operating Income-160.33-98.06-68.19-35.31-25.16
Interest Expense----0.37
Unusual Expense0.000.000.000.000.97
Net Income Before Taxes-145.09-86.97-61.92-32.56-26.14
Income Taxes0.000.000.000.000.00
Consolidated Net Income-145.09-86.97-61.92-32.56-26.14
Net Income From Continuing Operations-145.09-86.97-61.92-32.56-26.14
Net Income-145.09-86.97-61.92-32.56-26.14
EPS (Recurring)-2.99-2.38-1.85-0.98-0.76
EPS (Basic, Before Extraordinaries)-3.06-2.38-1.85-0.98-0.78
EPS (Diluted)-3.06-2.38-1.85-0.98-0.78
EBITDA-159.99-97.81-67.95-35.15-25.11
Non-Operating Income (Expense)15.2411.086.272.750.37
Other After Tax Adjustments0.000.000.000.000.00
Stock Option Compensation Expense41.758.685.222.040.31
Shares Outstanding49.6444.9333.4233.3833.38
Market Capitalization2,712.862,712.86615.88598.51-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.140.080.060.060.100.100.080.06
Gross Profit-0.14-0.08-0.06-0.06-0.10-0.10-0.08-0.06
Selling, General and Administrative Excl. Other66.2040.8527.2025.7323.8321.7026.4518.55
Research and Development32.0530.9818.4719.7619.2717.7222.4115.22
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-66.34-40.93-27.27-25.80-23.93-21.80-26.53-18.61
Interest Expense0.00-------
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-62.42-37.09-23.52-22.06-21.62-19.41-23.88-15.59
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-62.42-37.09-23.52-22.06-21.62-19.41-23.88-15.59
Net Income From Continuing Operations-62.42-37.09-23.52-22.06-21.62-19.41-23.88-15.59
Net Income-62.42-37.09-23.52-22.06-21.62-19.41-23.88-15.59
EPS (Recurring)-1.29-0.78-0.50-0.49-0.63-0.58-0.71-0.47
EPS (Basic, Before Extraordinaries)-1.29-0.78-0.50-0.49-0.63-0.58-0.71-0.47
EPS (Diluted)-1.29-0.78-0.50-0.49-0.63-0.58-0.71-0.47
EBITDA-66.20-40.85-27.20-25.73-23.83-21.70-26.45-18.55
Non-Operating Income (Expense)3.923.843.753.732.312.392.653.02
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense27.556.065.482.662.251.941.841.49
Shares Outstanding49.6447.9547.5744.9344.7233.5933.4233.42
Market Capitalization2,712.862,627.381,418.181,416.22588.13381.37246.67615.88

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY
Cash & Short Term Investments373.70262.1580.6842.46
Short Term Receivables2.120.680.210.14
Inventories0.000.000.000.00
Other Current Assets5.714.462.581.61
Total Current Assets381.54267.2983.4744.21
Net Property, Plant & Equipment3.221.200.670.84
Total Investments and Advances0.000.000.000.00
Intangible Assets0.000.00--
Other Assets0.380.050.050.04
Total Assets385.14268.5484.1845.09
Short Term Debt Incl. Current Port. of LT Debt0.170.170.150.14
Accounts Payable2.985.331.390.98
Other Current Liabilities12.355.542.382.32
Total Current Liabilities15.4911.053.933.43
Long Term Debt0.430.040.360.39
Provision for Risks Charges0.000.000.000.00
Other Liabilities0.000.000.000.00
Total Liabilities15.9211.094.293.82
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value0.000.00152.3683.88
Common Equity369.22257.44-72.47-42.60
Total Shareholders Equity369.22257.4479.8941.27
Accumulated Minority Interest0.000.000.000.00
Total Equity369.22257.4479.8941.27
Total Liabilities & Stockholders Equity385.14268.5484.1845.09
Book Value Per Share8.227.70-2.17-1.28
Tangible Book Value Per Share8.227.70-2.17-1.28
Full-Time Employees6343--
Price to Book Ratio5.912.272.20-
Return on Assets-26.61-35.11-50.38-
Return on Equity-27.76-36.71-53.75-
Return on Invested Capital-23.53-24.05-40.57-62.73
Quick Ratio24.6224.1921.2612.89
Current Ratio24.6224.1921.2612.89

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Net Income-145.09-86.97-61.92-32.56-26.14
Depreciation0.340.250.240.160.06
Other Funds (Non Cash)40.325.202.401.161.67
Funds from Operations-104.43-81.52-59.28-31.24-24.41
Extraordinary Item0.000.000.000.000.00
Changes in Working Capital8.421.574.60-0.731.29
Cash from Operating Activities-96.01-79.95-54.68-31.98-23.12
Capital Expenditures-3.32-1.93-0.87-0.13-0.44
Net Assets From Acquisitions0.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.00
Purchase or Sale of Investments-151.71-81.78-159.72-30.80-10.97
Purchase of Investments-443.20-358.15-239.47-63.80-20.22
Sale Or Maturity of Investments291.50276.3779.7533.009.25
Other Uses0.000.000.000.000.00
Other Sources0.000.000.000.000.00
Cash from Investing Activities-155.03-83.70-160.59-30.93-11.41
Cash Dividends Paid0.000.000.000.000.00
Change in Capital Stock189.81189.59234.1069.2236.09
Repurchase of Common Pref Stock0.000.000.000.000.00
Sale of Common Pref Stock189.81189.59234.1069.2236.09
Proceedsfrom Stock Options181.81187.18233.7068.4836.06
Issuance or Reduction of Debt, Net0.000.000.000.009.97
Change in Long Term Debt0.000.000.000.009.97
Issuance of Long Term Debt0.000.000.000.009.97
Reduction of Long Term Debt0.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.00
Cash from Financing Activities189.81189.59234.1069.2246.06
Net Change in Cash-61.2325.9418.836.3111.53
Free Cash Flow-99.33-81.88-55.55-32.11-23.56
Preferred Dividends (Cash Flow)-0.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments481.59418.58439.98373.70391.67224.91
Short Term Receivables3.233.043.162.121.550.84
Inventories0.000.000.000.000.000.00
Other Current Assets7.946.245.405.714.283.44
Total Current Assets492.76427.86448.54381.54397.50229.19
Net Property, Plant & Equipment7.617.423.593.222.522.28
Total Investments and Advances0.200.200.200.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.040.420.370.380.050.05
Total Assets500.62435.91452.70385.14400.08231.52
Short Term Debt Incl. Current Port. of LT Debt0.790.630.180.170.150.14
Accounts Payable6.804.366.972.983.775.76
Other Current Liabilities17.5718.677.4212.358.145.85
Total Current Liabilities25.1723.6614.5715.4912.0611.76
Long Term Debt2.502.710.380.430.480.53
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities27.6726.3714.9515.9212.5412.28
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity472.95409.54437.76369.22387.54219.24
Total Shareholders Equity472.95409.54437.76369.22387.54219.24
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity472.95409.54437.76369.22387.54219.24
Total Liabilities & Stockholders Equity500.62435.91452.70385.14400.08231.52
Book Value Per Share9.538.549.208.228.676.53
Tangible Book Value Per Share9.538.549.208.228.676.53
Full-Time Employees---63--
Price to Book Ratio5.916.003.633.642.681.62
Return on Assets-32.22-31.25-24.79-26.61-23.59-52.32
Return on Equity-33.72-33.17-25.73-27.76-24.43-56.28
Return on Invested Capital-13.13-9.00-5.37-5.97-5.57-8.83
Quick Ratio19.5818.0830.7924.6232.9519.50
Current Ratio19.5818.0830.7924.6232.9519.50

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-62.42-37.09-23.52-22.06-21.62-19.41
Depreciation0.140.080.060.060.050.06
Other Funds (Non Cash)27.495.764.942.131.541.00
Funds from Operations-34.79-31.25-18.51-19.87-20.02-18.35
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.088.63-1.691.57-1.510.92
Cash from Operating Activities-34.88-22.62-20.21-18.30-21.54-17.43
Capital Expenditures-1.19-0.90-0.44-0.79-0.40-0.71
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments44.0230.11-96.66-129.1817.4526.69
Purchase of Investments-29.73-53.89-154.16-205.43-46.40-47.43
Sale Or Maturity of Investments73.7584.0057.5076.2563.8574.12
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities42.8329.21-97.10-129.9717.0625.99
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock99.612.3287.440.44187.821.33
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock99.612.3287.440.44187.821.33
Proceedsfrom Stock Options97.200.1384.99-0.52187.690.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities99.612.3287.440.44187.821.33
Net Change in Cash107.578.91-29.87-147.84183.349.88
Free Cash Flow-36.07-23.52-20.64-19.09-21.93-18.14

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3014.05%4.3M30.5M513.07K
2026-10-1514.50%4.4M30.5M524.83K
2026-09-3014.64%4.5M30.5M575.69K
2026-09-1513.54%4.1M30.5M648.38K
2026-08-3113.62%4.2M30.5M748.82K
2026-08-1416.34%5.0M30.3M780.14K
2026-07-3117.46%5.2M29.7M851.00K
2026-07-1519.60%5.8M29.5M820.62K
2026-06-3020.02%5.9M29.4M745.10K
2026-06-1519.40%5.7M29.4M634.88K
2026-05-2916.34%4.8M29.4M571.37K
2026-05-1514.55%4.3M29.5M573.10K
2026-04-3013.68%4.0M29.5M545.18K
2026-04-1512.87%3.8M29.4M583.63K
2026-03-3112.68%3.6M28.3M635.02K
2026-03-1310.53%3.0M28.3M713.01K
2026-02-278.94%2.4M26.8M749.92K
2026-02-138.22%2.2M26.8M759.26K
2026-01-307.44%2.0M26.4M772.47K
2026-01-158.72%2.3M26.5M826.29K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call30.0025.2029.500.004.3110.000.000.938-0.1980.011
call35.0020.0024.500.003.5070.000.000.887-0.3180.017
call40.0015.0019.5011.002.80149.000.000.859-0.2960.020
call45.0010.7014.508.002.45020.000.000.817-0.2650.024
call50.006.5010.507.001.9086.000.000.706-0.4150.031
call55.003.507.003.301.73916.000.000.601-0.3260.034
call60.001.004.902.501.75215.000.000.473-0.3410.035
call65.000.004.101.401.93841.000.000.393-0.3740.034
call70.000.304.801.702.33949.000.000.352-0.4320.033
call75.000.002.151.602.0111.000.000.237-0.3090.028
call80.000.004.901.002.2412.000.000.219-0.3320.026
call85.000.004.901.002.5082.000.000.204-0.3510.025
call90.000.004.901.002.7165.000.000.193-0.3680.024
put30.000.000.950.003.1740.000.00-0.063-0.1930.011
put35.000.004.900.003.2500.000.00-0.115-0.3100.017
put40.000.004.901.102.5861.000.00-0.143-0.2880.020
put45.000.002.051.101.9873.000.00-0.183-0.2600.024
put50.000.004.906.302.3683.000.00-0.297-0.4040.031
put55.001.004.905.401.65636.000.00-0.399-0.3200.034
put60.003.507.508.301.5884.000.00-0.527-0.3350.035
put65.007.5011.0013.951.5995.000.00-0.610-0.3720.034
put70.0012.0015.700.001.8960.000.00-0.648-0.4240.033
put75.0016.5020.200.002.0670.000.00-0.762-0.2990.028
put80.0021.5025.500.002.3530.000.00-0.782-0.3260.026
put85.0026.5030.500.002.6370.000.00-0.796-0.3430.025
put90.0031.5035.000.002.5970.000.00-0.807-0.3620.024

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10144Filing for proposed sale of securities under Rule 144.SEC
2026-11-10S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-11-054Statement of changes in beneficial ownership of securities2026-11-04SEC
2026-11-05SCHEDULE 13G/ASEC
2026-11-04144Filing for proposed sale of securities under Rule 144.SEC
2026-10-224Statement of changes in beneficial ownership of securities2026-10-20SEC
2026-10-223Initial statement of beneficial ownership of securities2026-10-20SEC
2026-10-228-KCurrent report2026-10-20SEC
2026-08-278-KCurrent report2026-08-27SEC
2026-08-17144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-10SCHEDULE 13D/ASEC
2026-08-10SCHEDULE 13D/ASEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-08-04144Filing for proposed sale of securities under Rule 144.SEC
2026-08-04144Filing for proposed sale of securities under Rule 144.SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-07-29SCHEDULE 13GSEC
2026-07-138-KCurrent report2026-07-09SEC
2026-07-08SCHEDULE 13G/ASEC
2026-07-08SCHEDULE 13G/ASEC
2026-06-24SCHEDULE 13GSEC
2026-06-128-KCurrent report2026-06-12SEC
2026-06-10144Filing for proposed sale of securities under Rule 144.SEC
2026-06-09144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110020.13K1
2026-100000
2026-090000
2026-080024.33K1
2026-070000
2026-060000
2026-05002.71M3
2026-040000
2026-03525.66K100
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC15.30%
Frazier Life Sciences Management, L.P.13.98%
WELLINGTON MANAGEMENT GROUP LLP10.46%
NEA Management Company, LLC7.59%
ORBIMED ADVISORS LLC7.20%
BlackRock, Inc.6.98%
Paradigm Biocapital Advisors LP5.27%
NVP Associates, LLC4.49%
Deep Track Capital, LP3.64%
Polar Capital Holdings Plc3.38%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.39%
Eventide Healthcare & Life Sciences Fund1.84%
Fidelity Advisor Biotechnology Fund1.72%
iShares Russell 2000 ETF1.67%
Select Health Care Portfolio1.41%
Fidelity Stock Selector Small Cap Fund1.34%
T. Rowe Price Health Sciences Fund, Inc.1.23%
Fidelity Small Cap Growth Fund0.87%
Fidelity Series Small Cap Opportunities Fund0.77%
Fidelity Small Cap Index Fund0.71%

OakChart. MBX. Cached 15 minutes.